BRPI0507464A - formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida - Google Patents

formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida

Info

Publication number
BRPI0507464A
BRPI0507464A BRPI0507464-9A BRPI0507464A BRPI0507464A BR PI0507464 A BRPI0507464 A BR PI0507464A BR PI0507464 A BRPI0507464 A BR PI0507464A BR PI0507464 A BRPI0507464 A BR PI0507464A
Authority
BR
Brazil
Prior art keywords
salt
methyl
phenyl
methylpiperazin
ylamino
Prior art date
Application number
BRPI0507464-9A
Other languages
English (en)
Inventor
Hans Michael Buerger
Paul William Manley
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0507464A publication Critical patent/BRPI0507464A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

FORMAS DE SAL DE 4-(4-METILPIPERAZIN-1-ILMETIL)-N-¢4-METIL-3-((-PIRIDIN-3-IL)P IRIMIDIN-2-ILAMINO)FENIL!-BENZAMIDA. A presente invenção refere-se a sais de adição de ácido de 4-¢(4-metil-1-piperazinil)metil!-N-¢4-metil-3-¢¢4-(3-piridinil)-2-pirimidinil!a mino!fenil!-benzamida, selecionados do grupo consistindo em um sal tartarato, tal como (D)(-) ou um sal tartarato (L) (+), um sal cloridrato, um sal citrato, um sal maleato, um sal fumarato, um sal succinato, um sal benzoato, um sal benzenossulfonato, um sal pamoato, um sal formiato, um salmalonato, um sal 1,5-naftalenodissulfonato, um sal salicilato, um sal cicloexanodisulfamato,um sal, lactato um sal mandelato, um sal glutarato aquoso, um sal adipato, um sal esquarato, um sal vanilato, um sal oxaloacetato, um sal ascorbatoe um sal sulfato.
BRPI0507464-9A 2004-02-04 2005-02-03 formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida BRPI0507464A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04
PCT/EP2005/001077 WO2005075454A2 (en) 2004-02-04 2005-02-03 SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE

Publications (1)

Publication Number Publication Date
BRPI0507464A true BRPI0507464A (pt) 2007-07-10

Family

ID=34837520

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507464-9A BRPI0507464A (pt) 2004-02-04 2005-02-03 formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida

Country Status (22)

Country Link
US (3) US20080249104A1 (pt)
EP (1) EP1713792B1 (pt)
JP (1) JP4937760B2 (pt)
KR (2) KR20060135735A (pt)
CN (1) CN100558723C (pt)
AR (1) AR047530A1 (pt)
AU (1) AU2005211514B2 (pt)
BR (1) BRPI0507464A (pt)
CA (1) CA2553887C (pt)
EC (1) ECSP066752A (pt)
IL (1) IL177005A (pt)
MA (1) MA28428B1 (pt)
MY (1) MY144177A (pt)
NO (1) NO20063942L (pt)
NZ (1) NZ548714A (pt)
PE (1) PE20051096A1 (pt)
PH (1) PH12013500157A1 (pt)
RU (1) RU2375355C2 (pt)
TN (1) TNSN06243A1 (pt)
TW (1) TWI347186B (pt)
WO (1) WO2005075454A2 (pt)
ZA (1) ZA200605972B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
UY29964A1 (es) 2005-11-25 2007-06-29 Novartis Ag Formas de cristal f,g,h,i, y k del mesilato de imatinib
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
EP2086520A1 (en) 2007-09-25 2009-08-12 Teva Pharmaceutical Industries Ltd. Imatinib compositions
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
EP2445502B2 (en) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2775400A1 (en) 2009-09-28 2011-03-31 Medizinische Universitat Wien New use of pdgfrbeta inhibitors
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
KR20130055576A (ko) 2010-03-15 2013-05-28 낫코 파마 리미티드 고순도의 결정질 이마티닙 염기를 제조하는 방법
EA024088B1 (ru) 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
WO2013150052A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Soft chewable pharmaceutical products
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
CA3172586C (en) 2013-07-31 2025-10-14 Avalyn Pharma Inc. IMATINIB AEROSOL COMPOUNDS AND RELATED USES
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3691861B2 (ja) * 1994-09-14 2005-09-07 株式会社東芝 光ディスク用光パルス幅制御装置
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
ES2274234T3 (es) * 2002-03-15 2007-05-16 Novartis Ag 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
UY29964A1 (es) * 2005-11-25 2007-06-29 Novartis Ag Formas de cristal f,g,h,i, y k del mesilato de imatinib

Also Published As

Publication number Publication date
ECSP066752A (es) 2006-11-16
TW200529854A (en) 2005-09-16
CN1914191A (zh) 2007-02-14
MY144177A (en) 2011-08-15
CA2553887A1 (en) 2005-08-18
PE20051096A1 (es) 2006-01-23
TNSN06243A1 (en) 2007-12-03
AU2005211514B2 (en) 2009-09-10
US20140051853A1 (en) 2014-02-20
US8513256B2 (en) 2013-08-20
KR20060135735A (ko) 2006-12-29
NZ548714A (en) 2009-08-28
AR047530A1 (es) 2006-01-25
CN100558723C (zh) 2009-11-11
CA2553887C (en) 2013-04-16
AU2005211514A1 (en) 2005-08-18
ZA200605972B (en) 2007-11-28
KR20120127525A (ko) 2012-11-21
IL177005A0 (en) 2006-12-10
IL177005A (en) 2014-05-28
JP2007520518A (ja) 2007-07-26
US20120142697A1 (en) 2012-06-07
MA28428B1 (fr) 2007-02-01
RU2375355C2 (ru) 2009-12-10
WO2005075454A3 (en) 2006-07-27
WO2005075454A2 (en) 2005-08-18
US20080249104A1 (en) 2008-10-09
JP4937760B2 (ja) 2012-05-23
NO20063942L (no) 2006-11-02
EP1713792B1 (en) 2014-04-30
RU2006131548A (ru) 2008-03-10
PH12013500157A1 (en) 2014-09-08
TWI347186B (en) 2011-08-21
EP1713792A2 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
BRPI0507464A (pt) formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n[4-metil-3-((4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
TR200701870T1 (tr) İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
RU2009149216A (ru) Бициклические амиды как ингибиторы киназы
ATE321556T1 (de) Behandlung gastrointestinaler stroma-tumoren
PE20170004A1 (es) Inhibidores de biaril cinasa
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
IL223350A0 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
SG10201810057UA (en) Crystalline fgfr4 inhibitor compound and uses thereof
ATE481398T1 (de) Verfahren zur herstellung von imatinib-base
WO2009065910A3 (en) Acid addition salts of imatinib and formulations comprising the same
PH12021550456A1 (en) Crystalline forms of a quinazole compound and its hydrochloride salts
BR0307286A (pt) Tratamento de artrite reumatóide usando imatinib
WO2013120852A4 (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
UA101816C2 (en) Polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide
DE602004022540D1 (de) Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
TH74677A (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
NZ602758A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
DE602005025514D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
NO20075083L (no) 4-(pyrid-2-yl)-aminosubstituerte pyrimidiner som protein-kinase-inhibitorer
HK1106695A (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
TH102393A (th) การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.